Drug Information

Drug General Information
Drug ID
D0S2VD
Former ID
DNCL003460
Drug Name
Ibrutinib companion diagnostic
Indication Chronic lymphocytic leukaemia [ICD10:C91] Approved [551871]
Company
Abbott Laboratories; Janssen Biotech; Pharmacyclics
Target and Pathway
Target(s) Tyrosine-protein kinase BTK Target Info Inhibitor [532183]
KEGG Pathway NF-kappa B signaling pathway
Osteoclast differentiation
Platelet activation
B cell receptor signaling pathway
Fc epsilon RI signaling pathway
Primary immunodeficiency
PANTHER Pathway B cell activation
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells
BCR signaling pathway
FAS (CD95) signaling pathway
Class I PI3K signaling events
EPO signaling pathway
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
Reactome MyD88:Mal cascade initiated on plasma membrane
Regulation of actin dynamics for phagocytic cup formation
DAP12 signaling
FCERI mediated Ca+2 mobilization
MyD88 deficiency (TLR2/4)
IRAK4 deficiency (TLR2/4)
RHO GTPases Activate WASPs and WAVEs
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways Kit receptor signaling pathway
MyD88:Mal cascade initiated on plasma membrane
Signaling by the B Cell Receptor (BCR)
DAP12 interactions
B Cell Receptor Signaling Pathway
TSLP Signaling Pathway
Regulation of toll-like receptor signaling pathway
IL-5 Signaling Pathway
References
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 532183Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 2013 Mar;8(1):1-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.